A Phase I Study of MK-2206, an AKT Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumours or Leukaemia.

Trial Profile

A Phase I Study of MK-2206, an AKT Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumours or Leukaemia.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jan 2016

At a glance

  • Drugs MK 2206 (Primary)
  • Indications CNS cancer; Leukaemia; Lymphoma; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Apr 2013 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 23 May 2012 Planned end date changed from 1 Apr 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.
    • 03 Apr 2012 Additional lead trial centre and investigator identified as reported by Oregon Health and Science University Institutional Review Board.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top